A healthcare giant that runs thousands of CVS Pharmacy stores and MinuteClinic walk-in clinics, manages prescription drug benefits through CVS Caremark, and insures tens of millions of people through Aetna health plans. It was founded in 1963 in Lowell, Massachusetts as Consumer Value Stores — the initials that became its name — by brothers Stanley and Sidney Goldstein and partner Ralph Hoagland. In 2014 it became the first national pharmacy chain to stop selling tobacco, rebranding itself as CVS Health.
CVS net income nearly triples to $3.0B as prior-year litigation charges clear and insurance margins recover.
The insurance business continued its recovery, and a year-ago drag from litigation vanished. rose 7.3% to $106.1 billion and reached $2.31, up 188.8%, as swung from a $471 million to a $2.4 billion adjusted . The quarter resets the earnings baseline, but elevated medical utilization and pharmacy pricing pressure remain.
Key takeaways
rose 191.8% to $3.0 billion, driven by the absence of $833 million in legacy litigation charges recorded in Q2 2025 and improved Government business performance in the insurance .
adjusted rose 85.5% to $2.4 billion, helped by the absence of a $471 million individual exchange taken a year ago and improved star ratings.
adjusted grew 10.0% to $1.7 billion as improved purchasing economics and pharmacy drug mix more than offset continued client price improvements.
Section summaries
Management's Discussion and Analysis
CVS Health Q2 2026 net income nearly tripled to $3.0B, driven by improved Government business performance and absence of prior-year litigation charges.
⌄
Consolidated surged 97.5% to $4.7B, largely due to the absence of $833M in legacy litigation charges recorded in Q2 2025.
adjusted increased 10.2% to $1.5 billion, reflecting core pharmacy strength and contributions from Rite Aid asset acquisitions.
rose 234.5% to $6.3 billion in the quarter, and first-half operating cash flow reached $10.6 billion, up from $6.5 billion a year earlier, on improved insurance performance and payment timing.
widened 2.0 points to 70.3%, while rose 3.8% to $59.5 billion.
What changed
The $833 million in legacy litigation charges that depressed Q2 2025 did not recur, confirming the charges were one-time events as flagged in the prior-year Q2 watch items.
The individual exchange , which reached $471 million in Q2 2025 after $448 million in Q1 2025, was not repeated, suggesting the reserve proved adequate.
improved to 84.6% in Q1 2026 from 89.9% in Q2 2025, though the Q2 2026 MBR was not separately disclosed in this filing.
adjusted returned to growth at 10.0% after a 7.1% decline in Q1 2026, as purchasing economics and drug mix gains began to outpace client price improvements.
recovered sharply to $6.3 billion in Q2 after the $4.2 billion Q1 2026 figure that was down 6.7% , with the company again citing payment timing.
What to watch
Whether the can sustain the Q1 2026 level of 84.6% through the second half as Medicare utilization remains elevated and the 2027 rate proposal implies only a 0.09% average increase before risk score trend.
Whether adjusted growth continues after the 10.0% Q2 rise, or if pharmacy client price improvements again outpace purchasing economics gains.
Whether the $4.0 billion debt issued in August 2025 leads to higher in the second half of 2026 as it annualizes, with at $59.5 billion.
Whether can sustain the 10.2% adjusted growth as Rite Aid asset contributions annualize and pharmacy reimbursement pressure persists.
rose 85.5% to $2.4B, driven by improved Government business performance and the absence of a $471M .
grew 10.0% to $1.7B, benefiting from improved purchasing economics and pharmacy drug mix, partially offset by continued client price improvements.
increased 10.2% to $1.5B, reflecting core pharmacy strength and contributions from Rite Aid asset acquisitions.
Net increased $4.1B to $10.6B for the first half of 2026, driven by improved performance and timing of payments.
The company noted elevated medical utilization persists and expects continued pressure from sharing larger pharmaceutical rebates with clients.
Quantitative and Qualitative Disclosures About Market Risk
The Company has not experienced any material changes in exposures to market risk since December 31, 2025. See the information contained in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” of the Company’s Annual Report on Form 10-K for the fiscal yea…
⌄
The Company has not experienced any material changes in exposures to market risk since December 31, 2025. See the information contained in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for a discussion of the Company’s exposures to market risk.
The information contained in Note 8 ‘‘Commitments and Contingencies’’ contained in “Notes to Condensed Consolidated Financial Statements (Unaudited)” in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated by reference herein.
⌄
The information contained in Note 8 ‘‘Commitments and Contingencies’’ contained in “Notes to Condensed Consolidated Financial Statements (Unaudited)” in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated by reference herein.
There have been no material changes to the “Risk Factors” disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Those risk factors could adversely affect the Company’s businesses, operating results, cash flows and/o…
⌄
There have been no material changes to the “Risk Factors” disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Those risk factors could adversely affect the Company’s businesses, operating results, cash flows and/or financial condition as well as the market price of CVS Health Corporation’s common stock.